We hypothesized that single-nucleotide polymorphisms (SNPs) of genes involved in environmental endocrine disruptors (EEDs) metabolism might influence the risk of male genital malformations. In this study, we explored for association between 384 SNPs in 15 genes (AHR, AHRR, ARNT, ARNT2, NR1I2, RXRA, RXRB, RXRG, CYP1A1, CYP1A2, CYP1B1, CYP2B6, CYP3A4, CYP17A1 and CYP19A1) and risk of cryptorchidism (CO) and hypospadias (HS) in 334 Japanese (JPN) males (141 controls, 95 CO and 98 HS) and 187 Italian (ITA) males (129 controls and 58 CO). In the JPN study group, five SNPs from ARNT2 (rs2278705 and rs5000770), CYP1A2 (rs2069521), CYP17A1 (rs4919686) and NR1I2 (rs2472680) were significantly associated at both allelic and genotypic levels with risk of at least one genital malformation phenotype. In the ITA study group, two SNPs in AHR (rs3757824) and ARNT2 (rs1020397) were significantly associated with risk of CO. Interaction analysis of the positive SNPs using multifactor dimensionality reduction demonstrated that synergistic interaction between rs2472680, rs4919686 and rs5000770 had 62.81% prediction accuracy for CO (P ¼ 0.011) and that between rs2069521 and rs2278705 had 69.98% prediction accuracy for HS (P ¼ 0.001) in JPN population. In a combined analysis of JPN and ITA population, the most significant multi-locus association was observed between rs5000770 and rs3757824, which had 65.70% prediction accuracy for CO (P ¼ 0.055). Our findings indicate that genetic polymorphisms in genes involved in EED metabolism are associated with risk of CO and HS.
INTRODUCTION
During the early stages of development (embryonic, fetal and infant), humans are highly vulnerable to environmental hazards. It has been proposed that in utero exposure to environmental endocrine disruptors (EEDs) could adversely affect fetal growth and induce several types of male genital malformation (MGM), such as cryptorchidism (CO) and hypospadias (HS). 1,2 However, epidemiological studies on this issue have produced conflicting results. [3] [4] [5] The effect of EEDs would depend on several factors, including the dosage of EED exposure, the developmental stage in which EED exposure occurred and inter-individual variability in genetic susceptibility to the effects of EED exposure.
The etiology of MGM seems to be multifactorial, involving genetic, hormonal and environmental factors. Single-nucleotide polymorphism (SNP) analyses have been undertaken in human populations and have identified multiple genetic variants that are linked with the prevalence of MGMs. The majority of the previous studies have been performed to exploit polymorphisms in sex hormone and endocrine-related genes, such as insulin-like factor 3 (INSL3), INSL3 receptor (LGR8 or GREAT), androgen receptor, estrogen receptors 1 and 2 (ESR1 and ESR2), steroid-5a-reductase, mastermind-like domain containing 1 (Cxorf6), activating transcription factor 3, fibroblast growth factor 8 and FGF receptor 2. [6] [7] [8] [9] [10] [11] [12] However, few of these studies have focused on polymorphisms in genes involved in drug metabolism that might influence individual susceptibility to exogenous agents such as EEDs. It is well known that both the metabolism of EEDs and male sexual differentiation are mediated by a series of transcription factors and cytochrome P450 (CYP) enzymes. Genetic polymorphisms in these transcription factors and enzymes may be important in determining individual susceptibility to EED exposure and also in the development of MGMs. [13] [14] Both our study, and other previous studies have identified that genetic variants for ESR1 and ESR2 could raise the susceptibility of CO and HS by enhancing the effects of estrogenic EEDs, which are known as xenoestrogens and currently the largest group of known EEDs. 7, 15 In addition, several nuclear receptors, such as aryl-hydrocarbon receptor (AHR) and pregnane X receptor (PXR or NR1I2), are known to be crucial for EED-mediated CYP transcription. 16 Previous studies have reported that polymorphisms in AHR may affect AHR functions, notably the induction of CYP1 genes, suggesting a potential role for nuclear receptor polymorphisms in the variable responses to xenobiotic chemicals. 17 It is likely that further investigations of genetic polymorphisms involved in drug metabolism will shed increased light on the link between EED exposure and the development of MGMs.
Therefore, the aim of this study was to determine whether SNPs in genes involved in the metabolism of EEDs are associated with risk of CO and HS.
MATERIALS AND METHODS

Study populations
Gene selection
KeyMolnet, a knowledge-based information system developed by the Institute of Medicinal Molecular Design Inc., Tokyo, Japan, was used to identify the molecular interactions of four nuclear receptors (AHR, PXR or NR1I2, ESR1 and ESR2). KeyMolnet is a bioinformatics database composed of manually curated information on relationships among human genes, molecules, diseases, pathways and drugs from selected review articles, literature and public databases. It can generate networks from any molecule and can connect the networks to biological phenomena, and to drug and disease information. 18 From the generated network, CYP enzymes that are involved in the steroid hormone biosynthesis pathway were extracted for further analysis.
SNP selection
Selection of SNPs for use in this study was based on minor allele frequencies in the JPN populations with a location more than 60 kb distance from a range lying from 20 kb upstream of transcription to 10 kb downstream of each gene. They included known tagging SNPs, which are composed of a haplotype block.
Genotyping
The concentrations of the genomic DNA samples were determined with the PicoGreen dsDNA Quantitation kit according to manufacturer's protocol (Invitrogen, Carlsbad, CA, USA). SNPs were determined using the GoldenGate assay, which uses a human BeadArray technique (Illumina, San Diego, CA, USA), and allele-specific fluorescence signals were scanned using a BeadScan500 (Illumina).
Statistical analysis
Genotype frequencies in controls were tested for concordance with the HardyWeinberg equilibrium using GeneSpring software, version 11.5 (Silicon Genetics, Redwood City, CA, USA). Differences in all genotype frequencies between cases and controls were tested for each SNP. Odds ratios (ORs) for disease risk and corresponding 95% confidence intervals (CIs) were calculated at the genotypic level. The Cochran-Armitage trend test corrected with Benjamini-Hochberg false discovery rate and Fisher's exact test at the genotypic level were performed using GeneSpring software, version 11.5 (Silicon Genetics). In addition, multifactor dimensionality reduction (V2.0 Beta 8.4) analysis was performed to evaluate and validate main effects associated with the risk of CO and HS using a software package freely available online (www.epistasis.org). This algorithmic tool is a nonparametric (does not assume any statistical model) and model-free (no assumption mode of genetic inheritance) exploratory method, which has been developed to detect and characterize high-order gene-gene and gene-environment interactions in studies with relatively small sample size. 19, 20 Models are evaluated on the testing balanced accuracy, the cross-validation consistency and the statistical significance of the model. The testing balanced accuracy measures how often individuals are correctly classified with respect to their case/control status, and the cross-validation consistency evaluate the consistency with which individuals are classified. 21 Po0.05 was considered statistically significant in this study.
RESULTS
Gene and SNP selection
The molecular network was generated around four starting molecules (AHR, PXR or NR1I2, ESR1 and ESR2) within one path of both upstream and downstream from the starting point molecules by bioinformatics database tool (Figure 1 ). In addition to the four starting molecules, the generated network includes aryl-hydrocarbon receptor repressor (AHRR), aryl-hydrocarbon receptor nuclear translocator (ARNT), ARNT2, retinoid X receptor (RXR), and its three subtypes, RXRA, RXRB and RXRG, and 18 CYP enzymes. CYP enzymes involved in the steroid hormone biosynthesis pathway, which have been recognized as important targets for the actions of EEDs, 22 namely CYP1A1, CYP1A2, CYP1B1, CYP2B6, CYP3A4, CYP17A1 and CYP19A1, were selected for further analysis. Therefore, a total of 15 genes were selected as target genes for analyzing SNPs in this study (Table 1a and b). With the exception of RXRB, which had no tagging SNP, a total of 384 SNPs were detected in the remaining 14 genes.
Polymorphisms and CO risk in the JPN study SNPs found to be associated with risk of CO in the JPN population are shown in Table 2 . The minor homozygous rs5000770 (AA) of ARNT2, heterozygous rs4919686 (AC) of CYP17A1 and heterozygous rs247280 (AG) of NR1I2 were more frequently found in the 95 CO patients than in the 141 controls (OR ¼ 3.5, 95% CI ¼ 1.7-7.3; OR ¼ 3.3, 95% CI ¼ 1.4-7.8; and OR ¼ 2.2, 95% CI ¼ 1.0-5.0, respectively). Furthermore, the allele frequencies of these SNPs differed significantly between the CO patients and the controls (P trend o0.05).
Polymorphisms and HS risk in the JPN study
The SNPs found to be associated with risk of HS in the JPN study group are shown in Table 3 . Minor homozygous and heterozygous rs2069521 (AA and AG, respectively) of CYP1A2 and minor homozygous rs2278705 (AA) and minor homozygous rs5000770 (AA) of ARNT2 were more frequently found in the 98 HS patients than in the 141 controls (OR ¼ 4.5, 95% CI ¼ 9.3-194.6; OR ¼ 3.7, 95% Polymorphisms and CO risk in the ITA study The SNPs found to be associated with risk of CO in the ITA study group are shown in Table 4 . Heterozygous rs3757824 (AG) of AHR and minor homozygous and heterozygous rs1020397 (CC and CG, respectively) of ARNT2 were more frequently found in the 58 CO patients than in the 129 controls (OR ¼ 3.1, 95% CI ¼ 1.6-6.1; OR ¼ 3.4, 95% CI ¼ 1.3-8.9; and OR ¼ 2.8, 95% CI ¼ 1.3-5.8, respectively). The allele frequencies of these SNPs also differed significantly different between CO patients and controls (P trend o0.05). None of the SNPs positively associated with CO risk were found to be common to both JPN and ITA populations.
Possible gene-gene interaction in predisposition of CO and HS Table 5 presents the potential gene-gene interaction in predisposition for CO and HS among the positive SNPs identified in this study using multifactor dimensionality reduction analysis. For all possible interactions among the positively and negatively associated SNPs, the most significant gene-gene interplay were rs2472680-rs4919686-rs5000770 with a 62.81% prediction accuracy for CO (P ¼ 0.011) and rs2069521-rs2278705 with a 69.98% prediction accuracy for HS (P ¼ 0.001) in JPN population. In a combined analysis of JPN and ITA population, a multi-locus association was observed between rs5000770 and rs3757824, which had 65.70% prediction accuracy for CO (P ¼ 0.055).
DISCUSSION
This study was initiated to increase our understanding of the potential interaction of EED exposure and genetic factors on the risk of developing MGM. To achieve this aim, we sought to identify polymorphisms in genes involved in EED metabolism that were associated with an increased risk of CO and HS in a case-control study of populations from Japan and Italy. One of our most interesting results concerned SNP rs5000770 of ARNT2. We observed a significant association at both allelic and genotypic levels between rs5000770 genotype and the risk of both CO and HS in the JPN study group. Patients with the AA genotype had a significant increase in CO and HS risk compared with those with the GG genotype. Furthermore, synergistic interactions between rs5000770 and SNPs in NR1I2, CYP17A1, AHR and CYP1A2, which might confer susceptibility to both CO and HS in the JPN study group, were observed in the multifactor dimensionality reduction analysis. ARNT2 is a member of the basic helix-loop-helix Per-ARNT-SIM (bHLH-PAS) family of transcription factors that is involved in the regulation of many physiological pathways, including responses to environmental contaminants and oxygen deprivation, and for biological rhythms, angiogenesis and neuronal development. [23] [24] [25] Arnt2 has pivotal roles in the regulation of early development in zebrafish. 26 ARNT2 polymorphisms have been linked with the risk of some specific congenital malformations in humans such as cleft palate. 27 However, little is known about the relationship of ARNT2 polymorphisms and the risk of MGM. Recently, a new concept has been suggested that testicular cancer, CO and some cases of HS and impaired spermatogenesis are symptoms of a single underlying entity that has been named the testicular dysgenesis syndrome. 28, 29 This concept proposes the existence of a common underlying cause for the occurrence of these reproductive and developmental diseases, and suggests that adverse environmental factors such as EEDs might exert their etiological impacts under a susceptible genetic background. Our result indicates that variations in ARNT2 may be one of the possible common causes. One possible interpretation of our findings is that the A allele of ARNT2 might influence individual responsiveness to EEDs, and increase the risk of CO and HS. The SNP rs6163 of CYP17A1 is a common genetic polymorphism in the JPN population with a minor allele frequency of approximately 0.45. 30, 31 In the JPN group studied here, individuals with rs6163 CC genotype appeared to have an increased risk of CO. However, our statistical analysis suggested that the allele frequency difference between patients and controls for this SNP was only on the borderline of significance (P trend ¼ 0.067). It has been speculated that CYP17A1 variants might show differences in transcriptional efficiency and enzyme activity that, in turn, affect estrogen and androgen levels. 32 CYP17A1 variants have been shown to be associated with increased risk of diseases in which estrogens or androgens have an important role, such as breast cancer and prostate cancer. [33] [34] [35] Here we suggest that the rs6163 genotype might affect androgen homeostasis during fetal life and, thereby, increase the risk of MGM as male sexual differentiation is critically dependent on normal androgen concentrations. 36 At present, there is no information regarding any association between the rs6163 polymorphism and circulating hormone levels; however, another SNP (rs743572), which is also located in the 5 0 -untranslated region, has been extensively investigated and shown to be related to reduced messenger RNA levels in ovarian cells. 32 In addition, we observed a significant association at both allelic and genotypic levels between the SNP rs4919686 for CYP17A1 with risk of CO in the JPN study group. However, this variant is much less common than rs6163 and has only nine carriers in the control group.
The NR1I2 gene encodes the orphan nuclear receptor PXR, which has broad specificity and activates expression of CYP genes in response to a wide variety of xenobiotics. Following activation through ligand binding, PXR binds to the response element and induces the expression of CYP3A4, which has a major role in the hydroxylation of both estrone and estradiol. 16 EEDs, especially those with estrogenic effects, may modulate estrogen levels through PXR signaling. Polymorphisms in genes involved in PXR signaling may modify the adverse effect of EED exposure on estrogen levels. In postmenopausal women, an interaction effect between NR1I2 gene variants and phytoestrogen exposure has been reported to influence circulating sex hormone levels. 37 Our observation here that the heterozygous rs247280 genotype AG of NR1I2 is linked with an increased risk for CO in the JPN study group is consistent with this hypothesis. However, no significant association between CYP3A4 gene variants and risk of CO was found in this study.
The SNPs rs3757824 of AHR and rs1020397 of ARNT2 were associated with an increased risk of CO in the ITA study group but not in the JPN group. However, the interaction between rs3757824 and another polymorphism of ARNT2 (rs5000770) seems to confer susceptibility to CO in a combined analysis of JPN and ITA population (65.70% prediction accuracy, P ¼ 0.055). Previous studies have reported that genetic polymorphisms in AHR signaling may affect the induction of CYP1A1 and can be related to the risk of endocrine-related diseases, such as breast cancer. 38 A recent study has found a weak interaction effect between AHR rs3757824 and environmental risk factors on colorectal neoplasia. 39 The SNP rs2069521 of CYP1A2 was found to be significantly associated at both allelic and genotypic levels with risk of HS in JPN study group. CYP1A2 is one of the major CYP1 enzymes involved in the formation of catechol estrogens, which are known to be estrogenic and are thought to be carcinogenic. 40 One possible explanation for this finding may be due to linkage disequilibrium with other genetic variants. CYP1A2 variants are in linkage disequilibrium with CYP1A1 alleles, which themselves have been previously associated with the risk of infertility and HS. 13 Moreover, CYP1A1 and CYP1A2 share many of the same enzymatic activities and may be under coordinated regulation; placental expression and activity of CYP1A1 seem to be greater than for CYP1A2 and to occur earlier in pregnancy. 41 However, we did not find any positive CYP1A1 variants in this study.
We did not find any genetic polymorphisms in common between the JPN and ITA study groups for risk of CO. Various possible factors may underlie the apparent absence of shared polymorphisms. One possible contributing factor is the low number of cases in our study (95 in the JPN group and 58 in the ITA group). Another factor may be the differences between ethnic groups in allele frequencies. Indeed, a somewhat similar result was found in investigations of the association of ESR1 polymorphisms and CO risk in these two ethnic groups. In the JPN study group, five SNPs in the 3 0 region of the ESR1 gene (the AGATA allele) were found to be overrepresented in cryptorchid patients in comparison with controls (34.0 versus 21.3%), and homozygosity for this variant was found only in patients with undescended testes. 42 By contrast, in the ITA study population, the AGATA haplotype was found to be associated with a reduced risk of CO. 43 However, a rs5000770-rs3757824 interaction to susceptibility of CO was observed in the combined analysis of these two study groups. This interesting observation might explain partly the possible genetic effects masked by different gene-gene interaction leading to the controversial results in association studies, although further studies are necessary to confirm our findings in different ethnic groups. Our study has several potential limitations that should be taken into consideration. First, as the study group sizes were relatively small, then the statistical power for the detection of subtle changes might have been limited. Second, we hypothesized that the impaired function of proteins encoded by susceptibility genes might be caused by genetic polymorphisms, and that such impaired function might increase the risk of development of CO and HS. However, little is known of whether such genetic polymorphisms actually affect protein and/or cell functions. Therefore, further studies are needed to confirm our findings and to explore the possible molecular mechanisms of our observations.
In conclusion, this study suggests that polymorphism of genes involved in the metabolism of EEDs might have a significant role in the risk of development of CO and HS. The genes that were studied function in dioxin binding (AHR and ARNT2), dioxin induction (CYP1A2), estrogen synthesis (CYP17A1) and bisphenol A induction (NR1I2), suggesting a possible link between EED exposure and the development of MGMs. Inter-individual polymorphic differences might cause variations in sensitivity to the effects of EEDs as a potential cause of MGMs.
